NDA 050536 · Dr Reddys Labs SA
Eryc
Erythromycin · Oral · Macrolide; Macrolide Antimicrobial
Last checked: Nov 19, 2026Latest source record: Apr 23, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1981
Jan 26, 1981
Approved uses
1
Original approval plus efficacy supplements
Registered trials
915
219 Phase 3, 48 recruiting
FAERS reports
18,337
11,285 serious, 1,661 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Sep 25, 2025.
INDICATIONS AND USAGE Erythromycin is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes, Streptococcus pneumoniae, or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved) (see appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes. Listeriosis caused by Listeria monocytogenes. Pertussis (whooping cough) caused by Bordetella pertussis. Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheria e, as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Syphilis caused by Treponema pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy....
Mechanism: Mechanism of Action Erythromycin acts by inhibition of protein synthesis by binding 50 S ribosomal subunits of susceptible organisms. It does not affect nucleic acid synthesis. Resistance The major route of resistance is modification of the 23S rRNA in the 50S ribosomal subunit to insensitivity, while efflux can also be significant. Interactions With Other Antimicrobials Antagonism exists in vitro between erythromycin and clindamycin, lincomycin, and chloramphenicol. Erythromycin has been shown to be active against most isolates of the following bacteria both in vitro and in clinical...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 26, 1981 Original approval · Type 3 - New Dosage Form
1 products under this application
- ERYC · ERYTHROMYCIN 250MG · CAPSULE, DELAYED REL PELLETS, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Erythromycin" as an intervention, any sponsor and status, largest first.
- Azithromycin for Child Survival in Niger IIPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06358872 · 3,300,000 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 29, 2028
Drug: Azithromycin for Oral Suspension · For: Mortality; Antimicrobial Resistance
Sites: Niamey, Niger
- Azithromycin for Child Survival in Niger: Mortality and Resistance TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04224987 · 864,493 participants · Start Nov 24, 2020 · Primary completion Jul 31, 2024
Drug: Azithromycin · For: Mortality; Resistance Bacterial; Child, Only
Sites: Niamey, Niger
FHI 360Academic, hospital or other
NCT05016895 · 767,535 participants · Start Aug 27, 2021 · Primary completion Jun 30, 2024
Drug: Single-dose azithromycin · For: Child Mortality
Sites: Abidjan, Côte d’Ivoire
- Infant Mortality Reduction by the Mass Administration of AzithromycinPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT04716712 · 694,400 participants (planned) · Start Oct 4, 2021 · Primary completion Jan 30, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: San Francisco, California; Nouna, Burkina Faso; Ouagadougou, Burkina Faso
- Kebele Elimination of Trachoma for Ocular HealthPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT03335072 · 320,000 participants (planned) · Start Feb 7, 2022 · Primary completion Mar 1, 2027
Drug: Azithromycin · For: Trachoma
Sites: San Francisco, California; Bahir Dar, Ethiopia
- Mortality Reduction After Oral Azithromycin: Mortality StudyPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02047981 · 190,238 participants · Start Dec 2014 · Primary completion Sep 2018
Drug: Azithromycin; Placebo · For: Childhood Mortality
Sites: San Francisco, California; Baltimore, Maryland; Blantyre, Malawi · 6 sites in all
- Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)Pivotal-lookingTerminated
University of California, San FranciscoAcademic, hospital or other
NCT05288023 · 169,707 participants · Start Dec 1, 2022 · Primary completion Jan 15, 2024
Drug: Azithromycin for Oral Suspension · For: Resistance Bacterial; Morality; Child Health and 1 more
Sites: San Francisco, California
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in MaliPivotal-lookingCompleted
Tampere UniversityAcademic, hospital or other
NCT04424511 · 149,201 participants · Start Oct 15, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Azithromycin · For: Mortality
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug hypersensitivity4,099
- nausea1,272
- vomiting1,107
- drug ineffective1,100
- diarrhoea1,076
- fatigue1,058
- dyspnoea1,050
- rash1,018
- off label use953
- headache883
- dizziness791
- pain787
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 202 |
| 2005 | 231 |
| 2006 | 225 |
| 2007 | 209 |
| 2008 | 290 |
| 2009 | 424 |
| 2010 | 485 |
| 2011 | 443 |
| 2012 | 625 |
| 2013 | 574 |
| 2014 | 579 |
| 2015 | 664 |
| 2016 | 1,201 |
| 2017 | 1,085 |
| 2018 | 1,379 |
| 2019 | 1,759 |
| 2020 | 1,294 |
| 2021 | 1,299 |
| 2022 | 1,109 |
| 2023 | 1,260 |
| 2024 | 1,272 |
| 2025 | 1,079 |
| 2026 | 648 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of kerions.
Honig PJ, Caputo GL, Leyden JJ, et al. · Pediatr Dermatol 1994 · Clinical Trial, Randomized Controlled Trial
- Antibiotics for whooping cough (pertussis).
Altunaiji S, Kukuruzovic R, Curtis N, et al. · Cochrane Database Syst Rev 2005 · Meta-Analysis, Systematic Review
- Antibiotics for whooping cough (pertussis).
Altunaiji S, Kukuruzovic R, Curtis N, et al. · Cochrane Database Syst Rev 2007 · Meta-Analysis, Systematic Review
- Treating BCG-induced disease in children.
Cuello-García CA, Pérez-Gaxiola G, Jiménez Gutiérrez C · Cochrane Database Syst Rev 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Broad-spectrum antibiotics for preterm, prelabour rupture of fetal membranes: the ORACLE I randomised trial. ORACLE Collaborative Group.
Kenyon SL, Taylor DJ, Tarnow-Mordi W · Lancet 2001 · Clinical Trial, Multicenter Study
- Cyclosporin-erythromycin interaction in renal transplant patients.
Gupta SK, Bakran A, Johnson RW, et al. · Br J Clin Pharmacol 1989 · Clinical Trial, Randomized Controlled Trial
Sponsor: Dr Reddys Labs SA
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.